Skip to main content
. 2009 Nov 30;28(2):193–201. doi: 10.1200/JCO.2009.22.4279

Table 3.

Changes in Plasma Concentrations of Cytokines and Angiogenic Factors During Treatment

CAF and Treatment Arm Baseline
 Day 8
 Day 22
 Day 43
No. of Patients Median (pg/mL) Range (pg/mL) No. of Patients Median (pg/mL) Range (pg/mL) % Baseline* No. of Patients Median (pg/mL) Range (pg/mL) % Baseline* No. of Patients Median (pg/mL) Range (pg/mL) % Baseline*
VEGF
    V 55 102 0-1,246 45 105 0-1,160 98 35 97 0-880 105 31 128 0-289 138†
    CP 32 121 34-1,087 27 127 0-546 84 30 119 24-1,397 100 23 114 40-552 105
    VCP 36 118 0-4,024 32 140 16-3,606 101 29 124 16-3,744 93 26 117 6-1,041 111
sVEGFR-2
    V 54 9,593 4,100-16,732 45 8,443 2,257-21,598 93 34 8,414 3,429-14,483 90 29 7,290 3,429-14,483 85†
    CP 29 8,611 5,543-17,764 27 9,153 249-13,431 86† 28 8,877 3,110-15,457 95 22 9,097 939-16,897 92
    VCP 34 9,201 2,953-17,594 30 8,529 1,294-17,673 99 29 8,994 3,895-15,995 90 25 8,638 1,111-20,221 97
IL-12
    V 55 219 38-1,230 45 211 54-1,292 97 35 276 44-1,178 97 31 258 54-1,406 88
    CP 32 193 53-1,424 27 110 38-1,690 55† 30 199 37-1,774 91 23 193 58-1,380 79
    VCP 36 218 46-1,543 32 124 37-1,014 59† 29 192 37-858 79 26 198 32-785 84
IL-1RA
    V 55 610 150-6,234 45 599 175-11,929 101 35 750 148-8,626 101 31 643 197-8,121 104
    CP 32 493 188-27,612 27 338 88-18,191 66† 30 431 108-11,340 83 23 594 145-11,139 85
    VCP 36 600 130-11,201 32 347 102-11,005 71† 29 507 109-10,351 80 26 538 95-7,516 74
MMP-9
    V 55 38,592 5,742-892,964 45 35,458 2,749-980,916 106 35 39,045 5,750-211,208 123 31 32,037 2,752-402,460 108
    CP 32 45,165 6,305-2,500,000 27 24,574 1,771-188,733 51† 30 28,842 2,606-553,724 86 23 30,811 5,443-201,182 75
    VCP 36 30,703 6,198-393,092 32 25,560 2,119-122,638 80† 29 41,787 9,489-174,531 128 26 28,625 2,587-196,677 106
MCP-1
    V 55 349 132-2,841 45 370 117-7,539 109 35 416 141-3,270 102 31 370 133-4,743 126
    CP 32 358 140-4,587 27 576 147-3,161 136† 30 375 66-2,363 96 23 386 114-2,243 103
    VCP 36 387 41-5,226 32 458 221-5,732 139† 29 451 72-5,076 102 26 485 143-4,925 116
Eotaxin
    V 55 33 8-150 45 33 11-235 92 35 32 13-224 95 31 35 13-178 102
    CP 32 43 9-179 27 39 12-108 100 30 39 13-116 98 23 44 17-190 110
    VCP 36 43 7-108 32 45 10-102 110 29 47 7-114 129 26 53 14-121 121†
G-CSF
    V 55 94 1-1,733 45 77 1-3,393 100 35 79 1-825 111 31 101 6-564 116†
    CP 32 129 4-1,717 27 102 8-550 94 30 99 1-1,832 109 23 134 1-1,625 115
    VCP 36 92 1-3,792 32 95 1-3,252 110 29 92 1-3,511 91 26 104 1-2,991 101
IL-4
    V 55 24 0-750 45 24 0-727 100 35 22 0-368 109 31 31 0-209 100
    CP 32 23 0-217 27 17 0-267 79† 30 22 0-276 106 23 24 0-727 102
    VCP 36 19 0-652 32 20 0-798 99 29 26 0-491 109 26 25 0-579 105
IL-8
    V 55 41 2-2,644 45 49 2-417 115† 35 41 6-219 131 31 38 11-238 123
    CP 32 43 11-2,300 27 58 10-866 92 30 33 2-929 68 23 35 7-136 99
    VCP 36 53 4-711 32 59 12-362 118 29 35 7-213 80 26 40 9-279 104
IL-10
    V 55 86 1-2,273 45 68 1-1,669 101 35 71 6-924 111 31 63 2-1,400 117
    CP 32 80 15-6,176 27 64 10-2,044 63† 30 68 13-36,940 94 23 64 11-36,940 93
    VCP 36 50 9-36,940 32 54 7-36,940 106 29 61 6-36,940 102 26 52 13-6,870 123
IL-13
    V 55 83 2-1,401 45 90 2-1,542 100 35 103 2-750 100 31 90 2-382 107
    CP 32 95 2-1,598 27 78 2-926 81† 30 82 2-2,676 100 23 98 15-1,791 100
    VCP 36 82 2-2,163 32 80 2-2,701 98 29 74 2-2,229 100 26 67 2-2,151 100
IL-17
    V 55 95 0-2,483 45 78 0-2,694 100 35 63 0-2,400 100 31 104 0-1,548 128†
    CP 32 93 0-1,675 27 64 0-710 100 30 48 0-1,742 102 23 116 0-1,975 100
    VCP 36 75 0-2,028 32 69 0-2,439 100 29 57 0-1,393 94 26 28 0-1,959 100
IP-10
    V 55 35 5-328 45 45 6-151 81 35 53 9-264 118 31 62 5-505 147
    CP 32 36 9-889 27 30 12-265 105 30 30 6-106 96† 23 23 8-102 60†
    VCP 36 33 6-6,044 32 33 12-530 110 29 33 3-1,609 94 26 43 3-1,388 88
MIP-1α
    V 55 70 9-1,786 45 70 2-4,016 94 35 62 3-2,945 102 31 56 2-2,149 99
    CP 32 55 20-3,376 27 60 2-2,101 89† 30 53 17-1,427 102 23 77 19-1,830 101
    VCP 36 53 2-1,471 32 41 9-1,421 90 29 51 2-1,112 84 26 58 2-1,014 90

NOTE. The data presented in this table are based on the raw data prior to log2 transformation.

Abbreviations: CAF, cytokine and angiogenic factor; VEGF, vascular endothelial growth factor; V, vandetanib; CP, carboplatin and paclitaxel; VCP, vandetanib, carboplatin, and paclitaxel; sVEGFR-2, soluble vascular endothelial growth factor receptor 2; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; MMP-9, matrix metalloproteinase 9; MCP-1, macrophage chemoattractant protein 1; G-CSF, granulocyte colony-stimulating factor; IP-10, interferon gamma–induced protein 10; MIP-1α, macrophage inflammatory protein 1α.

*

Percent baseline indicates the median of the ratios of CAF concentration at each time point to baseline concentration expressed as a percentage (not the ratio of the median concentration at each time point to the median baseline concentration).

†

In the Cox proportional hazards model using log2 transformation of data, P < .05 for change in CAF concentration from baseline to time point.